Telemedicine services in community oncology practices.

Authors

Kah Poh Loh

Kah Poh Loh

University of Rochester Medical Center, Rochester, NY

Kah Poh Loh , Ying Wang , Chandylen L. Nightingale , Susan K. Parsons , Christa M. Braun-Inglis , Umang Gada , Alexander Montes , Eva Culakova , Allison Magnuson , Sule Yilmaz , Sarah Strause , Charles Stewart Kamen , Karen Michelle Mustian , Gary R. Morrow , Supriya Gupta Mohile

Organizations

University of Rochester Medical Center, Rochester, NY, University of Rocheser Medical Center, Rochester, NY, Wake Forest University School of Medicine, Winston-Salem, NC, Tufts Medical Center/Tufts University, Boston, MA, University of Hawaii at Manoa (Honolulu, HI), Honolulu, HI, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, University of Rochester, Rochester, NY

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health

Background: Telemedicine services have grown tremendously due to the COVID-19 pandemic. We described the use of telemedicine for research purposes at community oncology practices. Methods: We utilized results from the National Cancer Institute Community Oncology Research Program 2017 and 2022 Landscape Surveys, which were designed to understand cancer delivery research capacity in community oncology practices. We used multivariable logistic regression to examine factors associated use of telemedicine for research purpose in 2022, adjusting for region, practice ownership type, and number of oncology providers. Results: Information was available from 504 and 685 discrete practices in 2017 and 2022, respectively. These represent 210 and 259 practice groups; practice groups serving only pediatric patients were excluded. Mean numbers of oncology providers at the practice group level were 18 (IQR 5-21) and 20 (IQR 7-22) in 2017 and 2022, respectively. Over 90% of practice groups reported having outpatient electronic health records and patient portal in both years. In 2022, IT service was available onsite in 71%. In 2017, 31% of practice groups utilized telemedicine for delivery of cancer care and 15% can utilize telemedicine for research purposes. In 2022, telemedicine was used for research purposes in 73% of practice groups. Specifically, telemedicine was used for collection of patient-reported outcomes (54%), delivery of health care interventions (47%), consent (39%), conduct of qualitative interviews (32%), delivery of behavioral interventions (30%), collection of biometric data (e.g., weight, blood pressure) (14%), and collection of neurocognitive testing data (12%). One-third of all practice groups (35%) did not have internet-abled devices available for patients, 53% had them onsite, and 2% had them on site and for patients to take home. On multivariable analysis, a greater number of oncology providers was associated with greater use of telemedicine for research purposes (every 10-unit increase, AOR 1.31, 95% CI 1.04-1.64). Conclusions: From 2017 to 2022, there has been an increased use of telemedicine for research purposes, though its use varies across practices. Bigger practice groups were more likely to use telemedicine for research purpose. Cancer care delivery research that incorporates telemedicine should consider implementing site-specific and standardized resources.

AOR95% CI
Designation as a Critical Access Hospital1.260.51-3.11
Participation in Oncology Care Model0.550.28-1.06
No. of oncology providers, per 101.311.04-1.64
Utilization of APPs for oncology clinical care activities1.900.71-5.09
APP involvement in oncology clinical research activities1.680.88-3.20
No. of new cancer cases/year, per 1001.010.98-1.05
>10% of Medicaid-only/dual Medicare–Medicaid cases0.780.42-1.44

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Care Delivery and Regulatory Policy

Track

Care Delivery and Quality Care

Sub Track

Telemedicine/Remote Care

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e13678)

DOI

10.1200/JCO.2023.41.16_suppl.e13678

Abstract #

e13678

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

Tele-oncology implementation logic model.

First Author: Amir Alishahi Tabriz